Sanofi (SNY) Cut to “Underweight” at Morgan Stanley
Sanofi (NYSE:SNY) was downgraded by equities researchers at Morgan Stanley from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Friday, MarketBeat reports.
Other equities research analysts also recently issued reports about the stock. Argus reiterated a “buy” rating and set a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $53.50.
Sanofi (NYSE SNY) traded down $1.02 during trading hours on Friday, reaching $44.62. 1,767,991 shares of the company traded hands, compared to its average volume of 1,504,120. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. Sanofi has a twelve month low of $38.45 and a twelve month high of $50.65. The firm has a market cap of $112,590.00, a P/E ratio of 14.46, a PEG ratio of 2.53 and a beta of 0.88.
ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Cut to “Underweight” at Morgan Stanley” was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/12/01/sanofi-sny-cut-to-underweight-at-morgan-stanley.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.